BORTLIEVA 2 mg contains Bortezomib, a reversible proteasome inhibitor that inhibits the 26S proteasome. This leads to accumulation of misfolded proteins, disruption of cellular homeostasis, and apoptosis of malignant plasma cells. It is a key drug in multiple myeloma therapy.

Bortezomib is indicated for:

1. Multiple Myeloma
    – Newly diagnosed and relapsed/refractory

2. Mantle Cell Lymphoma (MCL)
    – Relapsed or refractory disease

Common side effects:

•  Peripheral neuropathy (dose-limiting)

•  Thrombocytopenia, anemia

•  Nausea, diarrhea, constipation

•  Fatigue

Other side effects:

•  Herpes zoster reactivation

•  Hypotension

Serious side effects:

•  Severe neuropathy

•  Heart failure (rare)

•  Pulmonary toxicity (rare)

Antiviral prophylaxis (e.g., acyclovir) is recommended.

Dosage is based on body surface area (BSA).

Standard dose:

•  1.3 mg/m² per dose

Schedule:

•  IV or SC on Days 1, 4, 8, and 11 of a 21-day cycle

    2 mg vial is commonly used for single-dose preparation.

NOTE: This medicine should be taken only under a doctor’s supervision.